Exhibit 99.1

Contact:
Mento A. "Chuck" Soponis
Chief Executive Officer
Oragenics, Inc.
(386) 418-4018

                                                           FOR IMMEDIATE RELEASE

                          ORAGENICS WARRANTS EXERCISED

Alachua FL (March 29, 2004) - Oragenics, Inc. (TSX-V:  ORA.U; OTC-BB: OGEN)
announced today that warrant holders exercised 83% of the 1,200,000  outstanding
Series B warrants  prior to their  expiration  on March 24,  2004.  Exercise  of
995,400  Series B warrants at the $3.00  exercise  price  resulted in a total of
$2,986,200 million (U.S.) received by the Company.

"We  are  appreciative  and  heartened  by the  support  our  shareholders  have
demonstrated  through the exercise of these  warrants,"  stated  Chuck  Soponis,
President & CEO of the company.  "The additional  capital  received by Oragenics
will strengthen our ability to move our development projects forward."

The Company has a total of 14,314,630 shares outstanding.

Oragenics,  Inc. is an emerging  biotechnology research and development company.
Located  in  Alachua,   Florida  at  the  University  of  Florida's  Sid  Martin
Biotechnology   Development   Incubator,   Oragenics  is  developing  three  new
healthcare  products.  The  most  advanced  product  is an  oral  rinse  for the
prevention of tooth decay,  which is  anticipated  to enter  clinical  trials in
2004.  The  second  product  in  pre-clinical  development  is a  broad-spectrum
antibiotic.  Oragenics is also  developing a probiotic  product to maintain oral
health.  For more  information  about  Oragenics,  please  consult the Company's
website at www.oragenics.com.

                                   # # # # # #

Safe Harbor  Statement  Under the Private  Securities  Litigation  Reform Act of
1995: This release includes forward-looking  statements which reflect Oragenics'
current  views with respect to future events and  financial  performance.  These
forward-looking statements are based on management's beliefs and assumptions and
information currently available.  The words "believe",  "expect",  "anticipate",
"intend",  "estimate",  "project"  and similar  expressions  which do not relate
solely to historical  matters  identify  forward-looking  statements.  Investors
should be cautious in relying on  forward-looking  statements  because  they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual  results  to  differ   materially   from  those  expressed  in  any  such
forward-looking  statements.  These factors include,  but are not limited to (1)
the  ability to  successfully  complete  development  and  commercialization  of
Oragenics'  technologies  and  products;  (2) the ability to obtain  substantial
additional funding; (3) the ability to develop and commercialize products before
competitors;  and (4) other  factors  detailed from time to time in filings with
the Securities and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking  statements. The TSX Venture Exchange has not reviewed
and does not accept  responsibility  for the  adequacy  or accuracy of this news
release.